KSF announces ADMA Biologics class action over August 2024-March 2026 period

The securities lawsuit, filed in New Jersey as Mazzarino v. ADMA Biologics, alleges undisclosed related-party dealings, channel stuffing and weak internal controls.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.